KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.

Andrew Alexis, Amy McMichael, Jennifer Soung, Olivia Choi, Theodore Alkousakis, Javier Alonso-Llamazares, Mona Shahriari, Adrian O Rodriguez, Tina Bhutani, Daphne Chan, Katelyn Rowland, Maxwell Sauder, H Chih-Ho Hong, Geeta Yadav, Jensen Yeung, Jenny Jeyarajah, Tony Ma, Long-Long Gao, Laura Park-Wyllie, Lawrence Green, Mark Lee, Neelam Vashi, Chesahna Kindred, Pearl Grimes, Susan C Taylor, Seemal R Desai, VISIBLE Trial Investigators

JAMA Dermatol 161(9) 901-911

PMID40560559
PMCIDPMC12199184
DOI10.1001/jamadermatol.2025.1836
发表日期2025-06-25
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 multi panel km;Figure 3:AI 判定为 multi panel km。
摘要

摘要

IMPORTANCE: Data and educational gaps in populations with skin of color contribute to racial and ethnic disparities in psoriasis treatment. Cohort A of the VISIBLE study includes participants with psoriasis who self-identify as belonging to a racial or ethnic category other than White, across the entire skin-tone spectrum. OBJECTIVE: To evaluate efficacy, quality of life, and adverse event outcomes among participants with moderate to severe psoriasis and skin of color who received guselkumab, 100 mg, for up to 48 weeks. DESIGN, SETTING, AND PARTICIPANTS: This ongoing phase 3b, randomized clinical trial at 39 sites in the US and Canada enrolled adults with skin of color and moderate to severe psoriasis (body surface area [BSA] ≥10%; Psoriasis Area and Severity Index [PASI] ≥12; Investigator's Global Assessment [IGA] ≥3). Data were collected from August 2022 to June 2024. INTERVENTIONS: Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0 and 4, then every 8 weeks, or placebo with crossover to guselkumab at weeks 16 and 20, then every 8 weeks. MAIN OUTCOMES AND MEASURES: Coprimary end points were IGA score of 0 or 1 (IGA 0/1) and PASI improvement of 90% or more (PASI 90) at week 16 (guselkumab vs placebo). Major secondary end points included IGA 0; PASI 100; percentage changes from baseline in PASI and BSA; changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms; and at least a 4-point reduction in PSSD itch. RESULTS: Of 103 participants (77 randomized to guselkumab; 26 randomized to placebo), 94 (91.3%) completed 48 weeks of treatment. The mean (SD) age overall was 44.1 (12.9) years, and 74 participants (71.8%) were male. At week 16, coprimary end points were achieved by greater proportions of guselkumab- vs placebo-treated participants (IGA 0/1: 57 of 77 [74.0%] vs 0 of 26; P < .001; PASI 90: 44 of 77 [57.1%] vs 1 of 26 [3.8%]; P < .001); 25 of 77 (32.5%) vs 0 of 26 achieved IGA 0 (P < .001), and 23 of 77 (29.9%) vs 0 of 26 achieved PASI 100 (P = .002). DLQI and PSSD symptoms score least-squares mean changes from baseline were -12.1 (95% CI, -13.1 to -10.9) vs -2.5 (95% CI, -4.4 to -0.6) (P < .001), and -49.4 (95% CI, -54.0 to -44.9) vs -8.2 (95% CI, -15.8 to -0.6) (P < .001), respectively. A 4-point or greater reduction in PSSD itch score was achieved by 48 (66.7%) vs 4 (16.7%) participants with a baseline score of at least 4 (P < .001). Efficacy increased and was maintained through week 48, with guselkumab-randomized participants achieving mean percentage improvements in PASI and BSA of more than 94%, and more than 50% of participants achieving complete clearance. Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, after 3 doses of guselkumab, significant skin clearance and quality of life improvements were observed in this cohort of participants with moderate to severe psoriasis and skin of color across the range of objectively measured skin tones. Improvements increased and were maintained through week 48. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05272150.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. VISIBLE Cohort A Study Design and Participant Disposition Through Week 48 a Coprimary end points are the proportions of participants achieving an Investigator’s Global Assessment score of 0 or 1 and 90% improvement in Psoriasis Area and Severity Index at week 16.
非 KM Figure
Figure 2Figure 2.. Clinical Responses in VISIBLE Cohort A Through Week 48 Proportions of participants achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 (A), Psoriasis Area and Severity Index (PASI) improvement of at least 90% (PASI 90) (B), IGA score of 0 (C), and PASI 100 (D). The mean percentage improvement in PASI and body surface area (BSA) over time are also presented (E and F). a Week 16, P < .001 for guselkumab vs placebo. b For participants who were randomized to placebo at week 0, only those who crossed over to guselkumab at or after week 16 were included in analyses after week 16. c Week 16, P = .002 for guselkumab vs placebo. d Week 16, P < .001 for guselkumab vs placebo based on the mixed model for repeated measures.
非 KM Figure
Figure 3Figure 3.. Key Patient-Reported Outcome End Points for VISIBLE Cohort A from Baseline to Week 48 Proportions of participants achieving Dermatology Life Quality Index (DLQI) of 0 or 1 (A); mean Psoriasis Symptoms and Signs Diary (PSSD) itch symptom scores (B); mean overall PSSD symptoms scores (C); and mean Skin Discoloration Impact Evaluation Questionnaire (SDIEQ) scores (D). a Among participants with DLQI of more than 1 at baseline. b Week 16, nominal P < .001 for guselkumab vs placebo. c For participants who were randomized to placebo at week 0, only those who crossed over to guselkumab at or after week 16 were included in analyses after week 16. d Week 16, P < .001 for guselkumab vs placebo based on the mixed model for repeated measures. e PSSD assessments were optional at weeks 28 and 36. f Week 16, P < .001 for guselkumab vs placebo based on the analysis of covariance model.
非 KM Figure